Phaseline

Targets › ABCC9

ABCC9 (ATP-binding cassette sub-family C member 9): drug programs, companies and trials

4 programs from 4 companies in 7 trials: 2 Phase 3, 2 Phase 4, 2 Phase 2, 1 Phase 1; Immunology, Oncology, Neurology; next expected readout Nov 2026.

Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. (UniProt, O60706)

Open in Phaseline: the race on ABCC9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Korea University Anam HospitalNicorandil
ATP-sensitive potassium channel opener with nitrate-like properties
ABCC9Phase 4No-Reflow PhenomenonMay 2027
Industrial Farmacéutica CantabriaMinoxidil
Sulfonylurea receptor 2, Kir6.2 opener
Ion channels, ABCC9Phase 3Androgenetic Alopecia; Central Centrifugal Cicatricial Alopecia (CCCA); Survivors of Childhood Cancer; Breast ReconstructionNov 2026
Zhejiang Sunshine Mandi PharmaceuticalMinoxidil
Sulfonylurea receptor 2, Kir6.2 opener
Ion channels, ABCC9Phase 3Androgenetic AlopeciaDec 2027
Gregory Jicha, MD, PhDNicorandil
ABCC9 (ATP-sensitive potassium channel) modulator
ABCC9Phase 2DementiaNov 2026

Conditions

Androgenetic Alopecia (2) Central Centrifugal Cicatricial Alopecia (CCCA) (1) Survivors of Childhood Cancer (1) Breast Reconstruction (1) Dementia (1) No-Reflow Phenomenon (1)

Modalities

small molecule (4)

Companies

Industrial Farmacéutica Cantabria (1) Gregory Jicha, MD, PhD (1) Zhejiang Sunshine Mandi Pharmaceutical (1) Korea University Anam Hospital (1)

Related targets

Ion channels (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.